Carmaphycin B-Based Proteasome Inhibitors to Treat Human African Trypanosomiasis: Structure–Activity Relationship and In Vivo Efficacy
ACS Infectious Diseases · 2024
DOI: 10.1021/acsinfecdis.4c00441 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Infectious Diseases, 2024. Verfasst von Lawrence J Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego…. Hauptthemen laut MEDLINE: Trypanosomiasis, African, Trypanosoma brucei brucei, Proteasome Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gates Foundation, NIAID NIH HHS, Clinical Center.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States.
- Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California 92093, United States.
- Department of Microbiology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG Brazil, 31270901.
- Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry and Tübingen Center for Academic Drug Discovery (TüCAD2), Eberhard Karls University Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany.
- School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio 70211, Finland.
- Partner-site Tübingen, German Center for Infection Research (DZIF), Elfriede-Aulhorn-Str. 6, 72076 Tübingen, Germany.
ORCID-Profile: Lawrence J Liu, Anthony J O'Donoghue, Conor R Caffrey
Förderung
- Gates Foundation
- NIAID NIH HHS
- Clinical Center
- University of Jordan
- Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico
- Bill and Melinda Gates Foundation
- Ministry of Higher Education
- United States Agency for International Development
Zitieren
APA
Liu, L. J., Francisco, K. R., Sun, Y. U., Serafim, M. S. M., Amarasinghe, D. K., Teixeira, T. R., Lucero, B., Kronenberger, T., Elsayed, W., Elwakeel, H., Al-Hindy, M., Almaliti, J., Gerwick, W. H., O'Donoghue, A. J., & Caffrey, C. R. (2024). Carmaphycin B-Based Proteasome Inhibitors to Treat Human African Trypanosomiasis: Structure–Activity Relationship and In Vivo Efficacy. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.4c00441
Vancouver
Liu LJ, Francisco KR, Sun YU, Serafim MSM, Amarasinghe DK, Teixeira TR, et al. Carmaphycin B-Based Proteasome Inhibitors to Treat Human African Trypanosomiasis: Structure–Activity Relationship and In Vivo Efficacy. ACS Infectious Diseases. 2024. doi:10.1021/acsinfecdis.4c00441
BibTeX
@article{Liu2024,
author = {Liu, Lawrence J and Francisco, Karol R and Sun, Yujie Uli and Serafim, Mateus Sá Magalhães and Amarasinghe, Dilini K and Teixeira, Thaiz R and Lucero, Bobby and Kronenberger, Thales and Elsayed, Waad and Elwakeel, Hala and Al-Hindy, Momen and Almaliti, Jehad and Gerwick, William H and O'Donoghue, Anthony J and Caffrey, Conor R},
title = {Carmaphycin B-Based Proteasome Inhibitors to Treat Human African Trypanosomiasis: Structure–Activity Relationship and In Vivo Efficacy},
journal = {ACS Infectious Diseases},
year = {2024},
doi = {10.1021/acsinfecdis.4c00441}
}
EUVIMED